These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8031055)

  • 41. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative serum bactericidal activity against Pseudomonas aeruginosa of six antipseudomonal agents.
    Dan M; Zabeeda D; Poch F
    Chemotherapy; 1995; 41(5):323-9. PubMed ID: 8521732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.
    Gai XY; Bo SN; Shen N; Zhou QT; Yin AY; Lu W
    Chin Med J (Engl); 2019 Mar; 132(6):638-646. PubMed ID: 30855292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.
    Guinea J; Gargallo-Viola D; Robert M; Tudela E; Xicota MA; Garcia J; Esteve M; Coll R; Pares M; Roser R
    Antimicrob Agents Chemother; 1995 Feb; 39(2):413-21. PubMed ID: 7726507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bactericidal activity of lomefloxacin SC 47111 (NY-198) and ciprofloxacin against selected pathogens.
    Stratton CW; Weeks LS
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):29S-34S. PubMed ID: 2791495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination effects of ciprofloxacin, clindamycin, and metronidazole intravenously in volunteers.
    Deppermann KM; Boeckh M; Grineisen S; Shokry F; Borner K; Koeppe P; Krasemann C; Wagner J; Lode H
    Am J Med; 1989 Nov; 87(5A):46S-48S. PubMed ID: 2589383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.
    Van der Auwera P; Klastersky J
    Antimicrob Agents Chemother; 1986 Dec; 30(6):892-5. PubMed ID: 3813515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
    Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
    Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections.
    Kljucar S; Heimesaat M; von Pritzbuer E; Timm J; Scholl H; Beermann D
    Am J Med; 1989 Nov; 87(5A):52S-56S. PubMed ID: 2589385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
    Richards RM; Hamilton VE; Thomas MR
    J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin.
    Van der Auwera P; Klastersky J
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1061-8. PubMed ID: 3116918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
    Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R
    Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.
    Gargallo-Viola D; Ferrer S; Tudela E; Robert M; Coll R; Roser R; Guinea J
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3113-21. PubMed ID: 11600365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.
    Marchbanks CR; McKiel JR; Gilbert DH; Robillard NJ; Painter B; Zinner SH; Dudley MN
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1756-63. PubMed ID: 8239581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries.
    Varela JE; Cohn SM; Brown M; Ward CG; Namias N; Spalding PB
    J Antimicrob Chemother; 2000 Mar; 45(3):337-42. PubMed ID: 10702553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
    Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
    Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.